Search

everythinglearnresearchcommunity

for

Search:↓

Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.

The document concludes that ERBB2 mutations are common in extramammary Paget disease and may respond to systemic treatments like cancer immunotherapy.

Kidney cancer cells without folliculin are more sensitive to radiation due to increased self-eating cell death.

Antioxidants can block the cancer-fighting effects of doxorubicin.

Upadacitinib helped regrow hair and maintain ulcerative colitis remission.

Females had more chemotherapy side effects than males, with many being preventable.

New cancer treatments aim to reduce side effects and improve effectiveness.

The Li-Pa/Ca and Do/Ca chemotherapy regimens for serous ovarian cancer showed better short-term and long-term results than the Pa/Ca regimen.

Microencapsulation helps protect and track therapeutic cells, showing promise for treating various diseases, but more work is needed to improve the technology.

Targeted cancer therapies often cause skin reactions, so dermatologists must manage these effects.

Some early breast cancer patients have long-term hair loss after chemotherapy, especially older and postmenopausal women.

Ritlecitinib works well and is safe for treating alopecia areata.

The document lists research on Pemetrexed and Cisplatin for lung cancer but doesn't give a final conclusion.

Gefitinib can cause scalp skin issues and permanent hair loss.

A reliable method was developed to measure Minoxidil and Tofacitinib in gel for hair loss treatment.

M30 is a promising treatment for preventing hair loss during chemotherapy.

Cetirizine may help treat hair loss safely by reducing scalp inflammation.

Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.

Mycophenolate mofetil is safer and more effective than cyclophosphamide for treating lupus nephritis.

Rituximab may cause skin issues, but baricitinib can help improve them.

Ascorbigen increases hair cell growth in a lab setting but does not prevent hair loss from chemotherapy in mice.

Deleting the MAD2L1 gene is tolerated in certain mouse cancer models.

Early intervention and tailored management can reduce skin side effects from cancer treatments.

Patients were very satisfied with hair regrowth after taking ritlecitinib for alopecia areata.

Baricitinib helps with early hair regrowth in people with alopecia areata.

Deleting the MAD2L1 gene in mice led to rapid tumor growth despite chromosomal instability.

The new drug delivery system effectively targets lung cancer cells.